Novo Nordisk reported a 16% sales increase in the first half of 2025, despite a recent profit warning that caused a 23% drop in share price. The company’s market capitalization has fallen significantly from €600bn to around €180bn. Analysts suggest the sell-off may be overdone, presenting a potential buying opportunity. Future sales are expected to grow 8-14%, but competition in the GLP-1 diabetes and weight-loss markets poses challenges. Leadership changes are also occurring, with a new CEO taking over soon.